Kintara Therapeutics Inc. (NASDAQ: KTRA)
$0.27
-0.0126 ( -4.41% ) 2.0M
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Market Data
Open
$0.27
Previous close
$0.29
Volume
2.0M
Market cap
$15.03M
Day range
$0.27 - $0.29
52 week range
$0.08 - $5.00
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Jul 12, 2024 |
8-k | 8K-related | 14 | Jul 08, 2024 |
8-k | 8K-related | 14 | Jul 01, 2024 |
8-k | 8K-related | 11 | Jun 24, 2024 |
8-k | 8K-related | 11 | Jun 13, 2024 |
8-k | 8K-related | 13 | Jun 03, 2024 |
def | Proxies and info statements | 15 | May 17, 2024 |
ars | Annual reports | 1 | May 17, 2024 |
8-k | 8K-related | 13 | May 14, 2024 |
10-q | Quarterly Reports | 61 | May 14, 2024 |